An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that CEO Pascal Touchon will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 12:00 p.m. PST. A live webcast of the presentation will be accessible on the company's website, with an archived replay available for 30 days. Atara is known for its innovative allogeneic Epstein-Barr virus (EBV) T-cell platform aimed at treating patients with serious diseases, including cancers and autoimmune disorders. The firm has advanced therapies such as tab-cel for EBV+ post-transplant lymphoproliferative disease and ATA188 for multiple sclerosis.
Positive
None.
Negative
None.
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.
A live webcast of the presentation will be available by visiting the Investor Events and Presentations section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in Southern California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.
When will Atara Biotherapeutics present at the H.C. Wainwright Cell Therapy Virtual Conference?
Atara Biotherapeutics will present at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 12:00 p.m. PST.
How can I access the Atara Biotherapeutics conference presentation?
You can access the Atara Biotherapeutics conference presentation via a live webcast on the company's website.
What is the focus of Atara Biotherapeutics' research?
Atara Biotherapeutics focuses on T-cell immunotherapy, particularly through its allogeneic Epstein-Barr virus T-cell platform for treating cancers and autoimmune diseases.
What therapies is Atara Biotherapeutics known for?
Atara Biotherapeutics is known for therapies such as tab-cel for EBV+ post-transplant lymphoproliferative disease and ATA188 for multiple sclerosis.
What is the stock symbol for Atara Biotherapeutics?
The stock symbol for Atara Biotherapeutics is ATRA.
